ADC Therapeutics Medical Information Hub
Search the Medical Information Library
Find answers to your inquiries about ADC Therapeutics products and pipeline from the Medical Information team.
Product
- Loncastuximab Tesirine
- Other Compounds
Indication / Disease
- DLBCL
- Other Select Heme Tumors
- FL
- MZL
- Select Solid Tumors
Media Type
Scientific Response Documents
Videos
Slides
Investigational Loncastuximab – LOTIS Clinical Trial Program
Medical Affairs
Product: Loncastuximab Tesirine, Other Compounds
Disease: DLBCL, Other Select Heme Tumors
Investigational Loncastuximab – LOTIS-5 Clinical Trial
Medical Information
Product: Loncastuximab Tesirine, Other Compounds
Disease: DLBCL
Investigational Loncastuximab – LOTIS-5 Infographic Clinical Trial and Data
Medical Affairs
Product: Loncastuximab Tesirine, Other Compounds
Disease: DLBCL
Investigational Loncastuximab – LOTIS-7 Clinical Trial
Medical Information
Product: Loncastuximab Tesirine, Other Compounds
Disease: DLBCL, Other Select Heme Tumors
Investigational Loncastuximab – LOTIS-7 Infographic Clinical Trial and Data
Medical Affairs
Product: Loncastuximab Tesirine, Other Compounds
Disease: DLBCL, Other Select Heme Tumors
Investigational Loncastuximab – LOTIS-7 Infographic Dosing
Medical Affairs
Product: Loncastuximab Tesirine, Other Compounds
Disease: DLBCL, Other Select Heme Tumors
Investigational Loncastuximab – NCCN Recommendation for FL
Medical Information
Product: Loncastuximab Tesirine
Disease: FL
Investigational Loncastuximab – Treatment of RR FL (IIT)
Medical Information
Product: Loncastuximab Tesirine
Disease: FL
Investigational Loncastuximab – Treatment of RR MZL (IIT)
Medical Information
Product: Loncastuximab Tesirine
Disease: MZL
Investigational Pipeline – ADCT Pipeline Slide Deck
Medical Affairs
Product: Loncastuximab Tesirine, Other Compounds
Disease: DLBCL, Other Select Heme Tumors, Select Solid Tumors
Loncastuximab (ZYNLONTA) – Adjusted Body Weight Formula and Rationale
Medical Affairs
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Bulky Disease and Burkitt Lymphoma
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Calculating Dose Based on ABW
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – CD19 Expression and Sequencing
Medical Affairs
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – CD19 Expression, Response and Treatment
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Concomitant Use with Vaccines
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Cough Incidence
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Cutaneous Reactions Management Flashcard
Medical Affairs
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Dose Response Infographic
Medical Affairs
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Dosing and Administration
Medical Affairs
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Drug Interactions
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Edema and Effusion Incidence & Management
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Effusion and Edema Management Flashcard
Medical Affairs
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Extravasation Incidence and Management
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Hepatic Enzyme Abnormalities Incidence
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Hypersensitivity Incidence & Management
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Inclusion of Patients with High Grade B-Cell Lymphoma
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL, Other Select Heme Tumors
Loncastuximab (ZYNLONTA) – Infection Prophylaxis
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Infusion Line of Administration
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Latex Content
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Liver Enzyme Elevation Incidence and Management
Medical Affairs
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – LOTIS-1 and Clinical Overview
Medical Affairs
Product: Loncastuximab Tesirine
Disease: DLBCL, Other Select Heme Tumors
Loncastuximab (ZYNLONTA) – LOTIS-1 Study
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL, Other Select Heme Tumors
Loncastuximab (ZYNLONTA) – LOTIS-2 and Clinical Overview
Medical Affairs
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – LOTIS-2 Study
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL, Other Select Heme Tumors
Loncastuximab (ZYNLONTA) – LOTIS-2 Subgroup Analysis
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Maximum Dose and Final Concentration
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Mechanism of Action
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Myelosuppression Incidence and Management
Medical Affairs
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Nausea and Vomiting Incidence
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – NCCN Recommendations for B Cell Lymphomas
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL, FL, MZL
Loncastuximab (ZYNLONTA) – Neutropenia Incidence
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Pharmacokinetics
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Premedication
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Prior & Post Radiation Use
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Prophylactic Use of Growth Factors
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Rationale for Dose Selection
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Reinitiation of Therapy after a Missed Cycle
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Renal Safety and PTLD
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Richter’s Transformation Incidence
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Skin Reactions
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Specific Gravity
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Stability with Alternative Dilution
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Storage and Stability of Vials
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Subsequent CAR-T Therapy
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Temperature Excursion Data
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Thrombocytopenia Incidence
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Tumor Lysis Syndrome Incidence
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Use Before or After Stem Cell Transplant
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Use in Elderly Patients
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Use in Overweight Obese Patients
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Use in Patients with CNS
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Use in Patients with Hepatic Impairment
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Use in Patients with p53 Mutation
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Use in Patients with Renal Impairment
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) – Use in Pregnancy and Lactation
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA) -Photosensitivity Rash Associated with Lonca Case Study
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA)- Effusion, Edema incidence and management
Medical Affairs
Product: Loncastuximab Tesirine
Disease: DLBCL
Loncastuximab (ZYNLONTA)-Rationale for ABW Calculation
Medical Information
Product: Loncastuximab Tesirine
Disease: DLBCL